Condition

Cardiomyopathy, Hypertrophic

ClinicalTrials.gov condition label

Clinical trials5

Recruiting0

Common interventions5

Lead sponsors shown5

Clinical trials

5 shown

A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure RiskNCT05646056 · 2022-10-28

UTSW HP [13-C] Pyruvate Injection in HCMNCT03057002 · 2018-05-01

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart FailureNCT02862600 · 2016-08-01

MRI Sequence and Imaging Protocol DevelopmentNCT03040947 · 2016-03-01

Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected MothersNCT00253682 · 2002-09-01

Common interventions

Cardiovascular Magnetic ResonanceOTHER1 Hyperpolarized 13C-PyruvateDIAGNOSTIC_TEST1 PerhexilineDRUG1 SoftwareDEVICE1 Use of bioanalytical assay to monitor plasma levels of perhexilineDEVICE1

Leading sponsors

Heart Metabolics Limited1 National Heart Centre Singapore1 Prolaio1 University of Miami1 University of Texas Southwestern Medical Center1

Trial status mix

COMPLETED3

TERMINATED1

UNKNOWN1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.